Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) yesterday. The company’s shares closed yesterday at $11.64. According to TipRanks, Werber is a 5-star ...

Vivek Ramaswamy will lead, together with Elon Musk, the Department of Government Efficiency (D.O.G.E) in the Donald Trump ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.26 per share a year ago. These ...

Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q2 2025 earnings on Nov 12, 2024. The consensus estimate for Q2 2025 ...

BASEL, Switzerland - Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for... Roivant (Nasdaq ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences (NASDAQ:ROIV), reported the exercise of a large sell of company stock options.

This page features the latest news about the Roivant Sciences stock. Roivant Sciences presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat Pulmovant, a Roivant ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...